Evidence map›Paper›PMID 28873137›Full record

SynthesisJAMA internal medicine2017

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

Rakesh Malhotra, Hoang Anh Nguyen, Oscar Benavente, Mihriye Mete, Barbara V Howard, Jonathan Mant, Michelle C Odden, Carmen A Peralta, Alfred K Cheung, Girish N Nadkarni and 7 more

Open access · greenAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in JAMA internal medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 8 pooled it
14.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 8 syntheses or guidelines pooled it, 204 citations in OpenAlex.

  1. Evaluating blood pressure targets in chronic kidney disease: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Pooled it
  2. Pooled it
  3. A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Guideline
  4. Pooled it
  5. Blood pressure targets in adults with hypertension.The Cochrane database of systematic reviews · 2020
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Atencion primaria · 2018
    Guideline
  9. Trial
  10. Trial
  11. Trial
  12. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  13. Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2019
    Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. 2024 Thai guidelines on the treatment of hypertension.Asian biomedicine : research, reviews and news · 2025
    Article
  19. Impact of intensive blood pressure control on kidney outcomes.Current opinion in nephrology and hypertension · 2025
    Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 5 countries.

Rakesh MalhotraDivision of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, La Jolla.
Hoang Anh NguyenDivision of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, La Jolla.
Oscar BenaventeDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, Canada.
Mihriye MeteDepartment of Biostatistics and Bioinformatics, MedStar Health Research Institute, Hyattsville, Maryland.
Barbara V HowardDepartment of Biostatistics and Bioinformatics, MedStar Health Research Institute, Hyattsville, Maryland.
Jonathan MantDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, England.
Michelle C OddenSchool of Biological and Population Health Sciences, Oregon State University, Corvallis.
Carmen A PeraltaDivision of Nephrology, Department of Medicine, University of California, San Francisco.
Alfred K CheungDivision of Nephrology and Hypertension, Department of Internal Medicine, University of Utah, Salt Lake City.
Girish N NadkarniDivision of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Ruth L ColemanDiabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, England.
Rury R HolmanDiabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, England.
Alberto ZanchettiIstituto Auxologico Italiano, Center of Clinical Physiology and Hypertension, Università Degli Studi di Milano, Milan, Italy.
Ruth PetersSchool of Public Health, Imperial College London, London, England.
Nigel BeckettCare of the Elderly, Imperial College London, London, England.
Jan A StaessenResearch Unit Hypertension and Cardiovascular Epidemiology, Katholieke Universiteit Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Joachim H IxDivision of Nephrology and Hypertension, Department of Medicine, University of California, San Diego, La Jolla.
University of California San Diego · USImperial College London · GBMedStar Health · USOxford Centre for Diabetes, Endocrinology and Metabolism · GBIcahn School of Medicine at Mount Sinai · USIRCCS Istituto Auxologico Italiano · ITMaastricht University · NLOregon State University · USUniversity of British Columbia · CAUniversity of California, San Francisco · USUniversity of Cambridge · GBUniversity of Utah · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
Kidney Tubular Damage and Dysfunction Identify a Novel Axis of Chronic Kidney DiseaseR01DK098234 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI IX, JOACHIM H, SHLIPAK, MICHAEL G · 2014 to 2023
$5.6M
CVD in American Indians Study and Data Management Center and OK Field CenterR01HL109284 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI STONER, JULIE A · 2013 to 2018
$4.6M
A New Paradigm for Hypertension in the Elderly- Beyond AgeR01AG046206 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ODDEN, MICHELLE CHRISTINA, PERALTA, CARMEN ALICIA · 2014 to 2018
$1.4M
Mentored Patient Oriented Research in Kidney DiseaseK24DK110427 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI IX, JOACHIM H · 2016 to 2020
$780k
NCATS NIH HHS UL1 TR001409NHLBI NIH HHS R01 HL109284NIA NIH HHS R01 AG046206NIDDK NIH HHS K24 DK110427NIDDK NIH HHS R01 DK098234
6 · The paper itself

Abstract

Importance: Trials in patients with hypertension have demonstrated that intensive blood pressure (BP) lowering reduces the risk of cardiovascular disease and all-cause mortality but may increase the risk of chronic kidney disease (CKD) incidence and progression. Whether intensive BP lowering is associated with a mortality benefit in patients with prevalent CKD remains unknown. Objectives: To conduct a systematic review and meta-analysis of randomized clinical trials (RCTs) to investigate if more intensive compared with less intensive BP control is associated with reduced mortality risk in persons with CKD stages 3 to 5. Data Sources: Ovid MEDLINE, Cochrane Library, EMBASE, PubMed, Science Citation Index, Google Scholar, and clinicaltrials.gov electronic databases. Study Selection: All RCTs were included that compared 2 defined BP targets (either active BP treatment vs placebo or no treatment, or intensive vs less intensive BP control) and enrolled adults (≥18 years) with CKD stages 3 to 5 (estimated glomerular filtration rate <60 mL/min/1.73 m2) exclusively or that included a CKD subgroup between January 1, 1950, and June 1, 2016. Data Extraction and Synthesis: Two of us independently evaluated study quality and extracted characteristics and mortality events among persons with CKD within the intervention phase for each trial. When outcomes within the CKD group had not previously been published, trial investigators were contacted to request data within the CKD subset of their original trials. Main Outcome and Measure: All-cause mortality during the active treatment phase of each trial. Results: This study identified 30 RCTs that potentially met the inclusion criteria. The CKD subset mortality data were extracted in 18 trials, among which there were 1293 deaths in 15 924 participants with CKD. The mean (SD) baseline systolic BP (SBP) was 148 (16) mm Hg in both the more intensive and less intensive arms. The mean SBP dropped by 16 mm Hg to 132 mm Hg in the more intensive arm and by 8 mm Hg to 140 mm Hg in the less intensive arm. More intensive vs less intensive BP control resulted in 14.0% lower risk of all-cause mortality (odds ratio, 0.86; 95% CI, 0.76-0.97; P = .01), a finding that was without significant heterogeneity and appeared consistent across multiple subgroups. Conclusions and Relevance: Randomization to more intensive BP control is associated with lower mortality risk among trial participants with hypertension and CKD. Further studies are required to define absolute BP targets for maximal benefit and minimal harm.

Indexed as

Antihypertensive AgentsBlood PressureDisease ProgressionHumansHypertension, RenalRenal Insufficiency, ChronicRisk FactorsAntihypertensive Agents

Identifiers

PMID28873137
PMCPMC5704908
OpenAlexW2753102265

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.